Title
Category
Credits
Event date
Cost
  • LivDerm
  • TME
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Atopic dermatitis (AD) is a chronic inflammatory and relapsing cutaneous disease characterized by pruritus, cutaneous inflammation, and transepidermal water loss (Krakowski 2008).  The incidence of AD in industrialized nations has increased by three-fold over a 30-year span, and it is estimated to affect between 15% and 30% of children in industrialized nations (Bieber 2010).  Although most children with AD will “outgrow” the disease, AD has additionally been reported to affect up to 10% of adults, and recent research suggests that AD is under-recognized in this group (Bieber 2010; Silverbe
  • LivDerm
  • TME
  • AAPA Category I CME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Timely and adequate treatment of atopic dermatitis (AD) is essential for helping to promote better long-term outcomes and quality of life. Targeted immunomodulatory agents, based on recent advances in the understanding of AD pathophysiology, represent additional options for long-term control. In particular, Janus kinase (JAK) inhibitors have emerged as a novel mechanism of action for treatment of AD.
  • CMHC
  • ABIM MOC and AMA PRA Category 1 Credit
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
Continuous glucose monitoring (CGM) has emerged as a clinically useful tool for the management of patients with type 2 diabetes, as it provides real-time data to better guide glycemic variability, improve glycemic control, as well as reduce the risk of hypoglycemia and hospitalizations.
  • CMHC
  • ABIM MOC and AMA PRA Category 1 Credit
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
This enduring clinical brief was developed from a primetime symposium at the 2021 CMHC Annual Congress. Moderated by Dr. Gregory Poland, the symposium reviewed the latest literature on the epidemiology, prevention, diagnosis, and treatment for influenza. The panel also highlighted the connection between influenza and other diseases, particularly its impact on cardiovascular diseases. There was an emphasis on the aspects that health care providers should focus on when treating patients with influenza.
  • CMHC
  • ABIM MOC and AMA PRA Category 1 Credit
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
This enduring clinical brief was developed from a primetime symposium at the 2021 CMHC Annual Congress. Moderated by Dr. Bakris, the symposium highlighted the importance of and the challenges in managing renal disease in patients with diabetes. The panel also gave a thorough background on the development of a non-steroidal mineralocorticoid receptor antagonist, a new drug class that shows promising results in tackling inflammation and fibrosis in patients with diabetes and renal disease.
  • LivDerm
  • TME
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Alopecia areata (AA) is an autoimmune disease that results in hair loss on the scalp and body. Currently,there is no FDA approved treatment for alopecia areata, challenging clinicians to find effectivetreatments in practice. However, recent findings have furthered understanding of AA, including thetargeting of specific immunologic pathways. Multiple clinical studies are underway investigating the useof Janus kinase (JAK) and TEC-family kinase inhibitors for treatment of moderate-to-severe AA.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
The coexistence of type 2 diabetes and chronic kidney disease significantly exacerbates cardiovascular and renal morbidity and mortality compared to either condition alone. Despite advances in therapy, many patients with DKD progress to kidney failure and have significant cardiovascular adverse events, and current strategies to address cardiorenal risk in these patients are inadequate.
  • LivDerm
  • TME
$0.00
**This activity has expired and is no longer eligible for CE credit. The content is still available to view.There is no doubt that clinicians have been exposed to more information about the human gut than ever before, and most practitioners treating skin disorders have had some form of education related to the skin microbiome.
  • CMHC
  • ABIM MOC and AMA PRA Category 1 Credit
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
GLP-1 RAs have carved an important role in the management of patients with type 2 diabetes (T2D), not only in glycemic control, but also in reducing cardiovascular and renal risk. The evolving evidence with GLP-1 RA in this setting has led to important studies and guideline changes, all with significant implications for patient management. This interactive infographic activity will walk you through these updates by using high-impact visuals to summarize the evidence, as well as added expert perspectives.
  • AANP
  • ACCME (All Other)
  • ACCME (MD/DO Only)
  • ACPE Pharmacy
  • ANCC
  • APA
$1,500.00

Pages